| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12975-017-0533-7 |
| P8608 | Fatcat ID | release_wivzsyqz5vaxxkr3jbh4y6ddwa |
| P698 | PubMed publication ID | 28405804 |
| P2093 | author name string | Paul A Lapchak | |
| Paul D Boitano | |||
| Jacqueline M Lara | |||
| P2860 | cites work | A call for transparent reporting to optimize the predictive value of preclinical research | Q24289327 |
| New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays | Q29615588 | ||
| Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke | Q29619330 | ||
| Tissue plasminogen activator for acute ischemic stroke | Q29619377 | ||
| Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association | Q30238784 | ||
| Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection | Q30275531 | ||
| Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials | Q30435728 | ||
| Thrombolytic therapy for ischemic stroke--a review. Part I--Intravenous thrombolysis | Q30664838 | ||
| Thrombolytic therapy for ischemic stroke--a review. Part II--Intra-arterial thrombolysis, vertebrobasilar stroke, phase IV trials, and stroke imaging | Q30664853 | ||
| Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials | Q31048053 | ||
| Neuroimaging as a Selection Tool and Endpoint in Clinical and Pre-clinical Trials. | Q31122611 | ||
| Newer thrombolytic agents | Q33781151 | ||
| Recommendations for standards regarding preclinical neuroprotective and restorative drug development | Q33785562 | ||
| Resolving the negative data publication dilemma in translational stroke research | Q33930564 | ||
| The use of animal models in diabetes research | Q34255921 | ||
| Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals | Q34372001 | ||
| Effect of the Pleiotropic Drug CNB-001 on Tissue Plasminogen Activator (tPA) Protease Activity in vitro: Support for Combination Therapy to Treat Acute Ischemic Stroke. | Q34432486 | ||
| Trends in thrombolytic use for ischemic stroke in the United States | Q34508464 | ||
| Feeling Nature's PAINS: Natural Products, Natural Product Drugs, and Pan Assay Interference Compounds (PAINS). | Q34515021 | ||
| Animal research: reporting in vivo experiments--the ARRIVE guidelines | Q34763016 | ||
| Development of thrombolytic therapy for stroke: a perspective | Q35001038 | ||
| Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3. | Q35128814 | ||
| A cost-effective rabbit embolic stroke bioassay: insight into the development of acute ischemic stroke therapy | Q35175537 | ||
| Critical early thrombolytic and endovascular reperfusion therapy for acute ischemic stroke victims: a call for adjunct neuroprotection. | Q36056147 | ||
| KNIME Workflow to Assess PAINS Filters in SMARTS Format. Comparison of RDKit and Indigo Cheminformatics Libraries | Q36088906 | ||
| Translational Stroke Research on Blood-Brain Barrier Damage: Challenges, Perspectives, and Goals. | Q36731242 | ||
| Metabolic Disorders and Diabetic Complications in Spontaneously Diabetic Torii Lepr (fa) Rat: A New Obese Type 2 Diabetic Model | Q36825735 | ||
| The spontaneously diabetic torii rat: an animal model of nonobese type 2 diabetes with severe diabetic complications. | Q36825739 | ||
| Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic molecules | Q36841904 | ||
| Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. | Q37301824 | ||
| Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies | Q37919706 | ||
| A series of novel neuroprotective blood brain barrier penetrating flavonoid drugs to treat acute ischemic stroke | Q38009074 | ||
| Combination of thrombolytic therapy and neuroprotective therapy in acute ischemic stroke: is it important? | Q38365586 | ||
| The High Cost of Stroke and Stroke Cytoprotection Research. | Q38776049 | ||
| Neurogenesis in Stroke Recovery | Q38778700 | ||
| Translational Hurdles in Stroke Recovery Studies | Q38783958 | ||
| Impact of Comorbidities on Acute Injury and Recovery in Preclinical Stroke Research: Focus on Hypertension and Diabetes | Q38793026 | ||
| Spontaneous and Therapeutic-Induced Mechanisms of Functional Recovery After Stroke | Q38816320 | ||
| Rodent Models of Vascular Cognitive Impairment | Q38920987 | ||
| Endovascular therapy for ischemic stroke with perfusion-imaging selection | Q39130456 | ||
| Chemical modification of the multitarget neuroprotective compound fisetin | Q39423915 | ||
| Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials | Q39933423 | ||
| Randomized assessment of rapid endovascular treatment of ischemic stroke | Q40256383 | ||
| Thrombectomy within 8 hours after symptom onset in ischemic stroke | Q41060802 | ||
| Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second-site' interactions | Q41774337 | ||
| The Importance of Considering Sex Differences in Translational Stroke Research | Q42085888 | ||
| Substrate specificity of tissue plasminogen activator and urokinase as determined with synthetic chromogenic substrates | Q42255060 | ||
| Recent Advances in Stem Cell-Based Therapeutics for Stroke | Q44836823 | ||
| Recommendations and practices to optimize stroke therapy: developing effective translational research programs | Q46072943 | ||
| Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes | Q46345427 | ||
| MRI Characterization in the Acute Phase of Experimental Subarachnoid Hemorrhage | Q47931980 | ||
| Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke | Q48225937 | ||
| A randomized trial of intraarterial treatment for acute ischemic stroke | Q48409278 | ||
| Early Endovascular Treatment in Intravenous Tissue Plasminogen Activator-Ineligible Patients | Q48883487 | ||
| Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry | Q48888166 | ||
| Extending the Time Window for Endovascular and Pharmacological Reperfusion. | Q51572286 | ||
| CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. | Q53475786 | ||
| Stem Cell Therapy and Administration Routes After Stroke. | Q54015446 | ||
| Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines-Stroke Hospitals | Q56336827 | ||
| Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma | Q68352987 | ||
| Production of plasminogen activator and plasminogen activator inhibitor by bovine lymphatic endothelial cells: modulation by TNF-alpha | Q68599014 | ||
| Determination of plasminogen activator inhibitor (PAI) activity of human plasma after dilution in a PAI-depleted plasma | Q69269023 | ||
| Current status of activity assays for tissue plasminogen activator | Q70515247 | ||
| Solution composition dependent variation in extinction coefficients for p-nitroaniline | Q71702452 | ||
| Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels | Q73606377 | ||
| Thrombolysis failure: a role for plasminogen activator inhibitor type 1 (PAI-1) | Q73942277 | ||
| Acceleration of thrombolysis with ultrasound through the cranium in a flow model | Q74173102 | ||
| Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials | Q81535162 | ||
| Animal Models for the Study of Subarachnoid Hemorrhage: Are We Moving Towards Increased Standardization? | Q87055652 | ||
| Clinical and Procedural Predictors of Outcomes From the Endovascular Treatment of Posterior Circulation Strokes | Q87314332 | ||
| P577 | publication date | 2017-04-12 | |
| P1433 | published in | Translational stroke research | Q26842494 |
| P1476 | title | Cytoprotective Drug-Tissue Plasminogen Activator Protease Interaction Assays: Screening of Two Novel Cytoprotective Chromones. |
Search more.